Prenetics Global Limited
Built from real-time financials, refreshed daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a PRE research report →
Range $35 – $54
Price Chart
About the company
Prenetics Global Limited is a consumer health sciences company that has pivoted to focus on a consumer health and longevity platform. The company's main brand is IM8, which offers science-backed nutritional supplements. It also operates CircleDNA, a consumer genetic testing brand that provides personalized health reports based on sequencing technology.
- CEO
- Sheng Wu Yeung
- IPO
- 2021
- Employees
- 98
- HQ
- Hong Kong, HK
Get TickerSpark's AI analysis on PRE
Create an account to generate AI analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →Already have an account? Log in
Similar companies
Peers in the same neighborhood.
- Market Cap
- $157.81M
- P/E
- -2.06
- Fwd P/E
- 6.38
- PEG
- 0.06
- P/S
- 1.02
- P/B
- 2.64
- EV/EBITDA
- -2.21
- Div Yield
- 0.00%
- Gross Margin
- 63.32%
- Op Margin
- -33.09%
- Net Margin
- -46.76%
- ROE
- -74.79%
- ROIC
- -44.71%
Latest fiscal year · YoY change
- Revenue
- $92.39M+201.7%
- Gross Profit
- $48.79M+216.8%
- Op Income
- $-38,129,000
- Net Income
- $-37,709,000+18.6%
- EPS
- $-2.68+26.4%
- OCF Growth
- +24.5%
- FCF Growth
- +26.5%
- 52W High
- $27.24
- 52W Low
- $8.69
- 50D MA
- $19.24
- 200D MA
- $19.37
- Beta
- 0.25
- RSI (14)
- 21
- Avg Volume
- 257.57K
Earnings call summaries
Pick a quarter — each call distilled into takeaways, results, and a bull vs bear read.
Prenetics reported another strong quarter of rapid IM8 growth, but chose to lean harder into customer acquisition and new product expansion, widening near-term EBITDA losses while reaffirming 2026 revenue guidance and a $400 million 2027 target.· November 18, 2026
- Q3 revenue was $64.1 million, with IM8 revenue of $62.9 million, and management said IM8 has now grown for six straight quarters.
- Adjusted free cash flow turned positive at $4.1 million, helped by $31.6 million of net funding from General Catalyst against $27.5 million of cash used in operations.
- Adjusted EBITDA loss widened to $12.7 million as the company stepped up marketing; management now expects a second-half 2026 adjusted EBITDA loss of $30 million-$35 million.
- Customer acquisition economics improved: CAC fell to about $285 from $301, while management said the first cohorts are returning $4.10 of gross profit per dollar spent and newer cohorts are around 2.7x LTV/CAC.
- Management reaffirmed 2026 revenue guidance of $220 million-$230 million for the group and IM8 revenue of $215 million-$222 million, and reiterated 2027 IM8 revenue guidance of $400 million or more on current products only.
Reported Q3 2026 revenue was $64.1 million, up 37.9% sequentially and about 3.3x Q3 2025; IM8 revenue was $62.9 million, up 39.8% sequentially and about 3.7x year over year. Gross margin was 64% in the quarter, with Brian Rosin saying it was held back by a one-time $1.3 million inventory charge related to older formulations and that margin should continue at 65% into Q4 and beyond. Contribution profit was $30.6 million, or 48% contribution margin; adjusted EBITDA loss was $12.7 million, versus negative 39% last quarter, and IFRS net loss was $25.4 million. Adjusted free cash flow was positive $4.1 million, cash and current financial assets ended at $111 million, and operating cash flow was negative $27.5 million offset by $31.6 million of net General Catalyst funding. Guidance was reaffirmed for full-year 2026 revenue of $220 million-$230 million, including IM8 revenue of $215 million-$222 million; implied Q4 revenue is about $73 million-$83 million for the group and $73 million-$80 million for IM8. Management also reiterated second-half 2026 adjusted EBITDA loss of $30 million-$35 million, expected IM8 annualized run-rate of at least $300 million by year-end, and 2027 IM8 revenue of $400 million or more on current products only, excluding Hydration, Care Bears, retail and China.
Danny Yeung framed the quarter as proof that the company should accelerate investment rather than pull back. He emphasized that the business is still early, that IM8’s core products are producing strong cohort returns, and that new launches like Hydration and Care Bears, plus retail and China, could add more growth engines beyond the current DTC base. His tone was highly confident and expansive, but he also said they will slow spending if CAC or cohort returns deteriorate.
Brian Rosin focused on leverage, financing structure, and balance-sheet strength. He cited 64% gross margin, $30.6 million of contribution profit, a $12.7 million adjusted EBITDA loss, and CAC of $285 on 137,892 new customers, with ad spend of $39.3 million. He said the General Catalyst facility is non-dilutive, produced $31.6 million of net cash funding in the quarter, and left the company with $111 million of cash and current financial assets at quarter-end. He also outlined long-term margin targets of 70%-75% gross margin, 8%-12% operating costs, 3%-5% brand royalty and ambassador costs, 35%-50% acquisition marketing, and 15%-25% adjusted EBITDA margin as the business matures.
Analysts pressed on retail and China, and management said retail is simpler and could go live by end of 2027, while China will require local partners because sales there run through third-party platforms like Tmall, JD, Douyin and Red Book. On CAC, Danny said the main driver of lower CAC is channel diversification rather than relying only on Meta, and he guided to roughly $300 CAC plus or minus 10%-15% over the next couple of quarters. When asked why revenue guidance was not raised despite higher marketing spend, Brian said the existing range was already wide and management wanted to preserve upside, while Danny said they prefer to leave room given the brand is only 22 months old. On financing, Brian said repayments will likely approach draws in about 18 months, but the company could become profitable faster if it slowed spending; for now, they are choosing growth.
The call presented a clear growth thesis: strong cohort returns, falling CAC, and a large market opportunity. Management said early cohorts have already exceeded a 3:1 gross profit return threshold, current cohorts are nearing it, and new products plus retail and China could expand the customer base without needing to rebuild the brand from scratch.
Near-term losses are increasing by design, and management explicitly lowered second-half EBITDA expectations to fund growth. The company is still heavily dependent on IM8 and on continued marketing efficiency, while key expansion bets like retail, China, Hydration, and Care Bears are not yet in guidance and still require execution, partnerships, and regulatory work.
AI summary of the company's earnings call · Paraphrased · Not investment advice
- Free Float
- 72.1%
- Shares Outstanding
- 17.93M
- Float Shares
- 12.94M
of shares held by institutions
27 13F filers
Buy/sell ratio 1.00. Sells can include pre-scheduled 10b5-1 plan sales, not just discretionary selling.
Congressional trading
Senate and House stock disclosures for PRE, newest first.
Source: public STOCK Act disclosures. Filed weeks after the trade — a lagging signal, not a real-time one.
Top institutional holders
Largest 13F positions, with quarter-over-quarter change.
| Holder | Shares | Δ Quarter |
|---|---|---|
| Prospect Capital Advisors, LLC | 401.15K | ▲ 165.35K |
| Ameriprise Financial Inc | 200.17K | ▲ 200.17K |
| Pillsbury Lake Capital LLC | 190.54K | ▲ 190.54K |
| Millennium Management LLC | 169.81K | ▲ 43.72K |
| 4d Advisors, LLC | 165.00K | ▲ 165.00K |
| Marshall Wace, Llp | 157.49K | ▲ 110.16K |
| Jane Street Group, LLC | 135.34K | ▼ 89.76K |
| Walleye Capital LLC | 125.88K | ▲ 125.88K |
| Point72 Asset Management, L.P. | 98.46K | ▲ 98.46K |
| Citadel Advisors LLC | 96.11K | ▲ 79.92K |
| Two Sigma Investments, LP | 87.29K | ▲ 87.29K |
| Xtx Topco Ltd | 81.90K | ▲ 51.42K |
Held by 9 ETFs
Biggest fund positions in PRE by dollar value.
Recent insider transactions
Who's buying, who's selling, and how much.
| Date | Insider | Type | Shares |
|---|---|---|---|
| Nov 18, 26 | Lo Hoi Chun | other | 8,446 |
| Nov 18, 26 | Lo Hoi Chun | sell | 45,815 |
| Nov 4, 26 | Leogrande Hudson Blake | other | 2,000 |
| Nov 4, 26 | Leogrande Hudson Blake | other | 2,000 |
| Oct 4, 26 | Leogrande Hudson Blake | other | 2,000 |
| Oct 4, 26 | Leogrande Hudson Blake | other | 2,000 |
| Sep 30, 26 | Lo Hoi Chun | other | 7,635 |
| Sep 30, 26 | Lo Hoi Chun | other | 7,635 |
| Sep 4, 26 | Leogrande Hudson Blake | other | 2,000 |
| Sep 4, 26 | Leogrande Hudson Blake | other | 2,000 |
A “Sell” may be a pre-scheduled 10b5-1 plan sale rather than a discretionary decision — read insider selling with that in mind.
Our PRE coverage
Recent articles, reports, and earnings notes.
No research on PRE yet
For a full analyst-grade research report — grades, price targets, financials, chart analysis — generate one on demand.
Generate PRE report →Prenetics: The Selloff Priced In The Spend, Not The Payback
seekingalpha.com · Nov 21
Prenetics (NASDAQ: PRE) raises 2026 revenue guidance and signs Diplo as a shareholder
defenseworld.net · Nov 19
Prenetics Global Limited (PRE) Q3 2026 Earnings Call Transcript
seekingalpha.com · Nov 18
What Prenetics Global (PRE) Said on Its Q3 Earnings Call
marketbeat.com · Nov 18
Prenetics' IM8 Reports Q3 2026 Revenue Growth of 266% YoY; Earliest Customers Have Returned More Than 3x Their Acquisition Cost in Under Two Years; Reaffirms FY 2026 Total Revenue Guidance of $220–230 Million and FY 2027 IM8 Revenue Guidance of $400 Million+
globenewswire.com · Nov 18
Prenetics' IM8 Announces Three-Time GRAMMY-Winning DJ and Producer Diplo as IM8 Global Ambassador and Shareholder in Multi-Year Partnership
globenewswire.com · Nov 16
Care Bears And Prenetics' IM8 Announce Global Partnership
prnewswire.com · Nov 5
Prenetics' IM8 and Authentic Brands Group Announce 10-Year Exclusive Global Partnership to Create Care Bears by IM8; Authentic to Become Strategic Shareholder in Prenetics
globenewswire.com · Nov 5
Headlines from third-party outlets — TickerSpark isn't affiliated with these sources.